New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
Autor: | Miran Javorovic, Dolores J. Schendel, Gunnar Kvalheim, Marion Subklewe, Felix S. Lichtenegger, Christiane Geiger, Iris Bigalke |
---|---|
Rok vydání: | 2014 |
Předmět: |
Cancer Research
Myeloid medicine.medical_treatment Immunology Hematopoietic stem cell transplantation Cancer Vaccines Immunotherapy Adoptive Mice Cancer immunotherapy medicine Animals Humans Immunology and Allergy business.industry Myeloid leukemia Dendritic Cells Immunotherapy Dendritic cell medicine.disease Minimal residual disease Disease Models Animal Leukemia Myeloid Acute Leukemia medicine.anatomical_structure Oncology business |
Zdroj: | Cancer Immunology, Immunotherapy. 63:1093-1103 |
ISSN: | 1432-0851 0340-7004 |
DOI: | 10.1007/s00262-014-1600-5 |
Popis: | Dendritic cell (DC)-based immunotherapy is a promising strategy for the elimination of minimal residual disease in patients with acute myeloid leukemia (AML). Particularly, patients with a high risk of relapse who are not eligible for hematopoietic stem cell transplantation could benefit from such a therapeutic approach. Here, we review our extensive studies on the development of a protocol for the generation of DCs with improved immunogenicity and optimized for the use in cell-based immunotherapy. This new generation DC vaccine combines the production of DCs in only 3 days with Toll-like receptor-signaling-induced cell maturation. These mature DCs are then loaded with RNA encoding the leukemia-associated antigens Wilm's tumor protein 1 and preferentially expressed antigen in melanoma in order to stimulate an AML-specific T-cell-based immune response. In vitro as well as in vivo studies demonstrated the enhanced capacity of these improved DCs for the induction of tumor-specific immune responses. Finally, a proof-of-concept Phase I/II clinical trial is discussed for post-remission AML patients with high risk for disease relapse. |
Databáze: | OpenAIRE |
Externí odkaz: |